These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17055409)

  • 1. Developing a paradigm of drug innovation: an evaluation algorithm.
    Caprino L; Russo P
    Drug Discov Today; 2006 Nov; 11(21-22):999-1006. PubMed ID: 17055409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The state of innovation in drug development.
    Kola I
    Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Structured introduction of new drug therapies: valuable initiative--transparency required].
    Lundkvist J; Henriksson F
    Lakartidningen; 2009 Jan 7-13; 106(1-2):51. PubMed ID: 19235324
    [No Abstract]   [Full Text] [Related]  

  • 5. Innovative strategies for early clinical R&D.
    Butz RF; Morelli G
    IDrugs; 2008 Jan; 11(1):36-41. PubMed ID: 18175261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The identification of benefit in medical intervention: an overview and suggestions for process.
    Stang PE; Pham SV; Kinchen K; Raff SB; Mussen F; Gondek K
    Am J Ther; 2008; 15(5):495-503. PubMed ID: 18806527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating post-marketing exposure to pharmaceutical products using ex-factory distribution data.
    Telfair T; Mohan AK; Shahani S; Klincewicz S; Atsma WJ; Thomas A; Fife D
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):749-53. PubMed ID: 16758501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [From the chemical product to the authorization of drug marketing].
    Caulin C
    Rev Prat; 2002 Mar; 52(5):486-90. PubMed ID: 11949499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system.
    Koh Y; Yap CW; Li SC
    Int J Med Inform; 2008 Jun; 77(6):421-30. PubMed ID: 17921048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A decision analytic approach to a futility analysis of a phase II pharmaceutical study.
    Pallay A
    J Biopharm Stat; 2001 Nov; 11(4):209-25. PubMed ID: 12018776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
    Reed SD; Califf RM; Schulman KA
    Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innovation strategies for generic drug companies: moving into supergenerics.
    Ross MS
    IDrugs; 2010 Apr; 13(4):243-7. PubMed ID: 20373253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [From molecule to medicine--drug development].
    Bruhn C
    Dtsch Med Wochenschr; 2010 Feb; 135(6):p5. PubMed ID: 20151355
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacometrics at FDA: evolution and impact on decisions.
    Powell JR; Gobburu JV
    Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug policy 1996].
    Bogaert M
    Verh K Acad Geneeskd Belg; 1997; 59(4):227-36. PubMed ID: 9490919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.